CASP3 and benign prostatic hyperplasia: Distinctively, the subsequent DIA treatment in the BPH+DIA group notably accentuated the cytoplasmic caspase 3 expression (Fig 6j) that showed a considerable rise at p<0.0001 opposite the control, DIA, and BPH groups.